Inovio Pharmaceuticals, Inc.

NasdaqCM INO

Inovio Pharmaceuticals, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -12,414,736.82%

Inovio Pharmaceuticals, Inc. EBT Margin is -12,414,736.82% for the Trailing 12 Months (TTM) ending September 30, 2024, a -64,322.84% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
  • Inovio Pharmaceuticals, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -19,270.71%, a -540.73% change year over year.
  • Inovio Pharmaceuticals, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -3,007.61%, a 10.38% change year over year.
  • Inovio Pharmaceuticals, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -3,356.12%, a 60.37% change year over year.
  • Inovio Pharmaceuticals, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -8,469.17%, a -364.38% change year over year.
Key data
Date EBT Margin Net Income Margin EBITDA Margin EBIT Margin
Market news
Loading...
NasdaqCM: INO

Inovio Pharmaceuticals, Inc.

CEO Dr. Jacqueline E. Shea Ph.D.
IPO Date Dec. 8, 1998
Location United States
Headquarters 660 West Germantown Pike
Employees 127
Sector Health Care
Industries
Description

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Similar companies

NVAX

Novavax, Inc.

USD 8.51

-1.16%

StockViz Staff

January 15, 2025

Any question? Send us an email